AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 272 min read$NTRA

RABINOWITZ DANIEL sold $8.5M of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 33,600 shares of Natera, Inc. (NTRA) at an average of $251.65 ($250.25–$253.39, $8.46M total) across 4 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jun 27, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 27, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity (legal officer selling shares) but does not introduce new operational, financial, or regulatory information about Natera.

02

Market read

Traders may treat this as a modest sentiment datapoint rather than a catalyst, given the pre-arranged 10b5-1 structure and lack of fundamental updates.

03

What to watch

The article provides sale size, price range, and post-trade holdings but no context on total compensation, prior sales cadence, or whether other insiders also sold around the same window.

Relevance 5/10Novelty 3/10Timing: Filed 2026-06-26 for sales executed 2026-06-24

Background

This is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz (SEC and Chief Legal Officer) sold 33,600 shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect would be sentiment/supply-related rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with defined dates/prices, but it does not disclose new company fundamentals or guidance changes.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, large insider sales can coincide with periods of valuation risk or personal liquidity needs, so traders may still watch for follow-on selling.

Key entities

  • company
    Natera, Inc.

    Issuer of the Form 4 insider transaction; shares sold by its SEC and Chief Legal Officer.

  • insider
    Daniel Rabinowitz

    Natera officer (SEC and Chief Legal Officer) who executed open-market sales under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

OCT 27
$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

finanznachrichten.de2 min
OCT 27
$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

investing.com2 min
OCT 27
$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

tradingview.com1 min
OCT 27
$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.

investing.com2 min